PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shares traded down 2.9% on Tuesday . The stock traded as low as $38.61 and last traded at $39.10. 132,714 shares traded hands during trading, a decline of 83% from the average session volume of 801,563 shares. The stock had previously closed at $40.27. Analyst Upgrades and […]
/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated.
- Dose-dependent lowering of blood Huntingtin protein levels at 12 weeks Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes -
- Conference call. | June 21, 2023
PTC Therapeutics Inc (NASDAQ: PTCT) shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease (HD) patients. The study demonstrated dose-dependent lowering of Huntingtin (HTT) protein levels in peripheral blood cells, reaching a mean 30% reduction in mutant HTT levels at the 10mg dose level. In addition, PTC518 exposure in the cerebrospinal fluid (CSF) was consistent with or higher than plasma unbound drug levels. PTC518 treatment was also well